A Phase I, Randomized, Investigator/Participant-Blind, Placebo-Controlled, Fixed-Sequence Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of Orally Administered RO7795081 and the Effect of Steady-State Dose of Orally Administered RO7795081 on the Pharmacokinetics of Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants
Latest Information Update: 27 May 2025
At a glance
- Drugs CT 996 (Primary) ; Pitavastatin (Primary) ; Rosuvastatin (Primary)
- Indications Obesity
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Roche
Most Recent Events
- 27 May 2025 New trial record